Related Experiment Video
Updated: Feb 16, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients
Alexandr Poprach1,2, Ondrej Fiala3,4, Renata Chloupkova5
1Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
Background:
Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy.
Patients And Methods:
The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed.
Results:
Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients.
Conclusion:
The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Insights
Pazopanib effectively treats metastatic renal cell carcinoma (mRCC) in the first-line setting. This study confirms its safety and efficacy, with median overall survival of 33.2 months.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- Pazopanib is an approved first-line treatment for metastatic renal cell carcinoma (mRCC).
- Real-world data on pazopanib's effectiveness and safety in mRCC patients are crucial.
Purpose of the Study:
- To evaluate the efficacy and safety of pazopanib as a first-line therapy for mRCC.
- To analyze patient outcomes and toxicity in a real-world setting.
Main Methods:
- Retrospective analysis of 426 mRCC patients treated with first-line pazopanib.
- Data sourced from the Renal Cell Carcinoma Information system registry.
- Analysis included baseline parameters, treatment, outcomes, and toxicity.
Main Results:
- Median progression-free survival (PFS) was 12.9 months and median overall survival (OS) was 33.2 months.
- Overall response rate (ORR) was 25.1% and disease control rate (DCR) was 57.4%.
- Treatment discontinuation due to adverse events occurred in 12.1% of patients.
Conclusions:
- Pazopanib demonstrates efficacy and safety as a first-line treatment for mRCC.
- Prognostic models (IMDC, MSKCC) are valid predictors of outcomes.
- Nephrectomy is associated with improved survival in mRCC patients.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
Renal Regulation of Acid-Base Balance
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...
Drug Elimination: Non-Renal Routes